Dimer Health

AiME does substantive clinical work: real time patient engagement, symptom interpretation against the individual's history, medications, and comorbidities, and continuous risk signal detection. Held back from A because what a health system buys is a staffed transitional care service in which a licensed Transitionist owns the episode; the AI is the monitoring and triage layer in front of a physician led practice rather than the deliverable itself.

The escalation target is named and accountable, which is what distinguishes a real oversight model from an assurance. AiME monitors and detects, then escalates to a dedicated Transitionist, a licensed clinician who owns the episode of care from discharge through recovery. Assigning ownership of the episode to a named human role, rather than routing alerts into a queue, is the correct design for the post discharge window where deterioration is the failure mode.

The company is credited with large reductions in avoidable readmissions, which is the right endpoint for transitional care and a measurable one. However no figure, cohort, study design, or named health system was retrieved, so the claim cannot be sized or verified. Readmission reduction is also heavily confounded by patient selection, making an unstated methodology a material gap. Founded 2023 with a Series A in March 2026.

No public pricing. Delivered as a clinical service line billed through health system and payor partnerships and aligned with value based care arrangements. Buyers should establish whether the economics are per episode, per member, or shared savings against readmission performance, since a service with clinical staffing costs behaves very differently from software under each.

Tightly and deliberately scoped to the transition from hospital discharge through recovery, a defined and clinically high risk window rather than general chronic care. Narrow scope precisely stated is what this axis rewards.